Page 12 - Flipbook
P. 12
Methods:
• 64 patients enrolled from 4 centres with very high risk node negative
prostate cancer: Gleason 9-10, >4 cores Gleason 8, or 2 high risk features
(including T3/T4 disease)
• Primary endpoint: Biochemical recurrence (BCR) (= PSA nadir +2)
